Mar 15, 2021 / 02:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Alzheimer's Update Conference Call. (Operator Instructions) As a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Sara Smith. Please go ahead.
Sara Smith - Eli Lilly and Company - Director of IR
Good morning. Thank you for joining us for Eli Lilly and Company's donanemab update. I'm Sara Smith, Director, Investor Relations. Joining me on today's call are Dr. Dan Skovronsky, Chief Scientific Officer; Dr. Mark Mintun, Vice President, Alzheimer's Disease Development Unit; and Dr. John Sims, Senior Medical Director for Donanemab.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including the extent and duration of the effects of the COVID-19 pandemic as well as other factors listed on Slide 3 and those outlined in our latest Forms 10-K, 10-Q and any 8-Ks filed with the Securities and
Eli Lilly and Co Alzheimer's Update at AD/PD Transcript
Mar 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers